Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › neuroblastoma

Neuroblastoma

Part of Germ cell tumors

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for neuroblastoma

44 trials tracked for neuroblastoma: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 262 citations.

44Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 29 Phase 1 6 Other / NA 7
  1. Phase 3 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed · 262 cited
  2. Phase 3 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma Completed · 130 cited
  3. Phase 2 A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Completed
  4. Phase 2 N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma Completed
  5. Phase 2 ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma Completed
  6. Phase 2 Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission Completed
Show 38 more trials
  1. Phase 2 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Completed
  2. Phase 2 Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma Completed
  3. Phase 2 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma Completed
  4. Phase 2 Study of MLN8237 in Combination With Irinotecan and Temozolomide Completed
  5. Phase 2 N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma Completed
  6. Phase 2 Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma Completed
  7. Phase 2 Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma Completed
  8. Phase 2 Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma Completed
  9. Phase 2 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed
  10. Phase 2 High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation Completed
  11. Phase 2 Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma Completed
  12. Phase 2 Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) Completed
  13. Phase 2 Therapy for Children With Advanced Stage Neuroblastoma Completed
  14. Phase 2 Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma Completed
  15. Phase 2 Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT Completed
  16. Phase 2 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Completed
  17. Phase 2 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma Completed
  18. Phase 2 Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Completed
  19. Phase 2 Oral Liquid 13-cis-retinoic Acid (13-CRA) Completed
  20. Phase 2 Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors Completed
  21. Phase 2 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow Completed
  22. Phase 2 Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Completed
  23. Phase 2 Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer Completed
  24. Phase 2 Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors Completed
  25. Phase 2 hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma Completed
  26. Phase 1 Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide Completed
  27. Phase 1 NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) Completed
  28. Phase 1 MIBG With Dinutuximab +/- Vorinostat Completed
  29. Phase 1 TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma Completed
  30. Phase 1 High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma Completed
  31. Phase 1 Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma Completed
  32. N/A Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer Completed
  33. N/A Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma Completed
  34. N/A Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma Completed
  35. N/A Molecular-Guided Therapy for Childhood Cancer Completed
  36. N/A Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients Completed
  37. N/A High-Risk Neuroblastoma Chemotherapy Without G-CSF Completed
  38. N/A Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant Completed

Showing the 44 most-cited and recently-updated of 44 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
AI-derived nomograms outperform conventional markers for risk stratification and prognosis in neuroblastoma
Oncology Meta-analysis
AI-derived nomograms outperform conventional markers for risk stratification and prognosis in neuroblastoma Artificial intelligence shows promise in identifying neuroblastoma risks
This meta-analysis of 53 studies evaluates machine learning models and hybrid nomograms for neuroblastoma diagnosis and risk stratification.…
New analysis shows artificial intelligence tools may outperform traditional methods in identifying risks and outcomes for children with neur…
Sep 9, 2026
Insufficient evidence exists to determine the independent clinical contribution of GM-CSF to anti-GD2 immunotherapy
Oncology Meta-analysis
Insufficient evidence exists to determine the independent clinical contribution of GM-CSF to anti-GD2 immunotherapy Evidence Lacks Clarity on GM-CSF Impact for Neuroblastoma Treatment
This systematic review evaluates the efficacy and safety of anti-GD2 immunotherapy with and without GM-CSF in patients with neuroblastoma. T…
Current research cannot determine if adding GM-CSF improves the effectiveness or safety of anti-GD2 immunotherapy for patients with neurobla…
Frontiers Sep 8, 2026
Phase II pilot study of hu14.18K322A plus chemotherapy in 153 children with high-risk neuroblastoma
Pediatrics Phase II
Phase II pilot study of hu14.18K322A plus chemotherapy in 153 children with high-risk neuroblastoma New Antibody Boosts Survival in High-Risk Neuroblastoma
This Phase II pilot study enrolled 153 previously untreated children with high-risk neuroblastoma. The study assessed hu14.18K322A combined …
This study shows that combining a new antibody with standard chemotherapy may improve survival rates for children with high-risk neuroblasto…
CT.gov Jun 4, 2026
Review examines multi-omics approaches to enhance diagnostic precision and treatment decisions in pediatric neuroblastoma
Pediatrics Sys. Review
Review examines multi-omics approaches to enhance diagnostic precision and treatment decisions in pediatric neuroblastoma The AI Tool That's Changing How Doctors Fight Childhood Cancer
This narrative review evaluates the application of multi-omics approaches, including transcriptomics and radiomics, for children with neurob…
A new AI tool combines genetic tests and imaging to help doctors diagnose and treat unpredictable childhood cancer called neuroblastoma more…
Frontiers Apr 18, 2026